Review




Structured Review

CSL Behring rhdl csl-111
Rhdl Csl 111, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhdl+csl-111/csl+111/pmc07226336-139-4-7
Average 90 stars, based on 1 article reviews
rhdl csl-111 - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

IV Injection:

Article Title: Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation
Article Snippet: Enrolled patients continued all their existing medications except for statins which were discontinued from 1 week prior to the infusion and recommenced following the atherectomy/angioplasty. rHDL and infusion protocol The study was double blinded and the rHDL (CSL Behring AG, Bern, Switzerland; CSL-111; 80 mg/kg; comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150) or placebo (saline) was administered over a 4 hr period as previously described 7 .

Article Title: Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Article Snippet: The rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150.

Article Title: High-Density Lipoproteins Are Bug Scavengers
Article Snippet: Finally, we recently tested rHDL (CSL-111 from CSL Behring) IV injection two hours after sepsis in three preclinical models: CLP, intraperitoneal injection of E. coli (IAI76 strain) and P. aeruginosa pneumonia.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human ApoA-I or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Article Snippet: rHDL (CSL-111, CSL Behring) is composed of purified serum derived human apoA-I (hapoA-I) and soy PC, combined at amolar ratio of 1:150 [56].

Article Title: CETP expression reverses the reconstituted HDL-induced increase in VLDL
Article Snippet: Upon randomization according to total plasma cholesterol (TC) and TG levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, Bern, Switzerland) (250 mg/kg in 250 μl PBS) or vehicle.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human apoAI or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 comprises human apoAI and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Article Snippet: We would like to thank CSL Behring AG, Bern, Switzerland, for supplying the rHDL (CSL-111) and Melissa Formosa and Donna Vizi for assistance with the clinical trial.

Injection:

Article Title: Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation
Article Snippet: Enrolled patients continued all their existing medications except for statins which were discontinued from 1 week prior to the infusion and recommenced following the atherectomy/angioplasty. rHDL and infusion protocol The study was double blinded and the rHDL (CSL Behring AG, Bern, Switzerland; CSL-111; 80 mg/kg; comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150) or placebo (saline) was administered over a 4 hr period as previously described 7 .

Article Title: Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Article Snippet: The rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150.

Article Title: High-Density Lipoproteins Are Bug Scavengers
Article Snippet: Finally, we recently tested rHDL (CSL-111 from CSL Behring) IV injection two hours after sepsis in three preclinical models: CLP, intraperitoneal injection of E. coli (IAI76 strain) and P. aeruginosa pneumonia.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human ApoA-I or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Article Snippet: rHDL (CSL-111, CSL Behring) is composed of purified serum derived human apoA-I (hapoA-I) and soy PC, combined at amolar ratio of 1:150 [56].

Article Title: CETP expression reverses the reconstituted HDL-induced increase in VLDL
Article Snippet: Upon randomization according to total plasma cholesterol (TC) and TG levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, Bern, Switzerland) (250 mg/kg in 250 μl PBS) or vehicle.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human apoAI or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 comprises human apoAI and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Article Snippet: We would like to thank CSL Behring AG, Bern, Switzerland, for supplying the rHDL (CSL-111) and Melissa Formosa and Donna Vizi for assistance with the clinical trial.

Purification:

Article Title: Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation
Article Snippet: Enrolled patients continued all their existing medications except for statins which were discontinued from 1 week prior to the infusion and recommenced following the atherectomy/angioplasty. rHDL and infusion protocol The study was double blinded and the rHDL (CSL Behring AG, Bern, Switzerland; CSL-111; 80 mg/kg; comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150) or placebo (saline) was administered over a 4 hr period as previously described 7 .

Article Title: Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Article Snippet: The rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150.

Article Title: High-Density Lipoproteins Are Bug Scavengers
Article Snippet: Finally, we recently tested rHDL (CSL-111 from CSL Behring) IV injection two hours after sepsis in three preclinical models: CLP, intraperitoneal injection of E. coli (IAI76 strain) and P. aeruginosa pneumonia.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human ApoA-I or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Article Snippet: rHDL (CSL-111, CSL Behring) is composed of purified serum derived human apoA-I (hapoA-I) and soy PC, combined at amolar ratio of 1:150 [56].

Article Title: CETP expression reverses the reconstituted HDL-induced increase in VLDL
Article Snippet: Upon randomization according to total plasma cholesterol (TC) and TG levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, Bern, Switzerland) (250 mg/kg in 250 μl PBS) or vehicle.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human apoAI or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 comprises human apoAI and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Article Snippet: We would like to thank CSL Behring AG, Bern, Switzerland, for supplying the rHDL (CSL-111) and Melissa Formosa and Donna Vizi for assistance with the clinical trial.

Derivative Assay:

Article Title: Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation
Article Snippet: Enrolled patients continued all their existing medications except for statins which were discontinued from 1 week prior to the infusion and recommenced following the atherectomy/angioplasty. rHDL and infusion protocol The study was double blinded and the rHDL (CSL Behring AG, Bern, Switzerland; CSL-111; 80 mg/kg; comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150) or placebo (saline) was administered over a 4 hr period as previously described 7 .

Article Title: Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Article Snippet: The rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150.

Article Title: High-Density Lipoproteins Are Bug Scavengers
Article Snippet: Finally, we recently tested rHDL (CSL-111 from CSL Behring) IV injection two hours after sepsis in three preclinical models: CLP, intraperitoneal injection of E. coli (IAI76 strain) and P. aeruginosa pneumonia.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human ApoA-I or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Article Snippet: rHDL (CSL-111, CSL Behring) is composed of purified serum derived human apoA-I (hapoA-I) and soy PC, combined at amolar ratio of 1:150 [56].

Article Title: CETP expression reverses the reconstituted HDL-induced increase in VLDL
Article Snippet: Upon randomization according to total plasma cholesterol (TC) and TG levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, Bern, Switzerland) (250 mg/kg in 250 μl PBS) or vehicle.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human apoAI or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 comprises human apoAI and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Article Snippet: We would like to thank CSL Behring AG, Bern, Switzerland, for supplying the rHDL (CSL-111) and Melissa Formosa and Donna Vizi for assistance with the clinical trial.

Clinical Proteomics:

Article Title: Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation
Article Snippet: Enrolled patients continued all their existing medications except for statins which were discontinued from 1 week prior to the infusion and recommenced following the atherectomy/angioplasty. rHDL and infusion protocol The study was double blinded and the rHDL (CSL Behring AG, Bern, Switzerland; CSL-111; 80 mg/kg; comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150) or placebo (saline) was administered over a 4 hr period as previously described 7 .

Article Title: Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Article Snippet: The rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150.

Article Title: High-Density Lipoproteins Are Bug Scavengers
Article Snippet: Finally, we recently tested rHDL (CSL-111 from CSL Behring) IV injection two hours after sepsis in three preclinical models: CLP, intraperitoneal injection of E. coli (IAI76 strain) and P. aeruginosa pneumonia.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human ApoA-I or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Article Snippet: rHDL (CSL-111, CSL Behring) is composed of purified serum derived human apoA-I (hapoA-I) and soy PC, combined at amolar ratio of 1:150 [56].

Article Title: CETP expression reverses the reconstituted HDL-induced increase in VLDL
Article Snippet: Upon randomization according to total plasma cholesterol (TC) and TG levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, Bern, Switzerland) (250 mg/kg in 250 μl PBS) or vehicle.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human apoAI or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 comprises human apoAI and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Article Snippet: We would like to thank CSL Behring AG, Bern, Switzerland, for supplying the rHDL (CSL-111) and Melissa Formosa and Donna Vizi for assistance with the clinical trial.

Emulsion:

Article Title: Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation
Article Snippet: Enrolled patients continued all their existing medications except for statins which were discontinued from 1 week prior to the infusion and recommenced following the atherectomy/angioplasty. rHDL and infusion protocol The study was double blinded and the rHDL (CSL Behring AG, Bern, Switzerland; CSL-111; 80 mg/kg; comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150) or placebo (saline) was administered over a 4 hr period as previously described 7 .

Article Title: Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Article Snippet: The rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150.

Article Title: High-Density Lipoproteins Are Bug Scavengers
Article Snippet: Finally, we recently tested rHDL (CSL-111 from CSL Behring) IV injection two hours after sepsis in three preclinical models: CLP, intraperitoneal injection of E. coli (IAI76 strain) and P. aeruginosa pneumonia.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human ApoA-I or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Article Snippet: rHDL (CSL-111, CSL Behring) is composed of purified serum derived human apoA-I (hapoA-I) and soy PC, combined at amolar ratio of 1:150 [56].

Article Title: CETP expression reverses the reconstituted HDL-induced increase in VLDL
Article Snippet: Upon randomization according to total plasma cholesterol (TC) and TG levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, Bern, Switzerland) (250 mg/kg in 250 μl PBS) or vehicle.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human apoAI or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 comprises human apoAI and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Article Snippet: We would like to thank CSL Behring AG, Bern, Switzerland, for supplying the rHDL (CSL-111) and Melissa Formosa and Donna Vizi for assistance with the clinical trial.

Medications:

Article Title: Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation
Article Snippet: Enrolled patients continued all their existing medications except for statins which were discontinued from 1 week prior to the infusion and recommenced following the atherectomy/angioplasty. rHDL and infusion protocol The study was double blinded and the rHDL (CSL Behring AG, Bern, Switzerland; CSL-111; 80 mg/kg; comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150) or placebo (saline) was administered over a 4 hr period as previously described 7 .

Article Title: Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Article Snippet: The rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150.

Article Title: High-Density Lipoproteins Are Bug Scavengers
Article Snippet: Finally, we recently tested rHDL (CSL-111 from CSL Behring) IV injection two hours after sepsis in three preclinical models: CLP, intraperitoneal injection of E. coli (IAI76 strain) and P. aeruginosa pneumonia.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human ApoA-I or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Article Snippet: rHDL (CSL-111, CSL Behring) is composed of purified serum derived human apoA-I (hapoA-I) and soy PC, combined at amolar ratio of 1:150 [56].

Article Title: CETP expression reverses the reconstituted HDL-induced increase in VLDL
Article Snippet: Upon randomization according to total plasma cholesterol (TC) and TG levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, Bern, Switzerland) (250 mg/kg in 250 μl PBS) or vehicle.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human apoAI or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 comprises human apoAI and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Article Snippet: We would like to thank CSL Behring AG, Bern, Switzerland, for supplying the rHDL (CSL-111) and Melissa Formosa and Donna Vizi for assistance with the clinical trial.

Saline:

Article Title: Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation
Article Snippet: Enrolled patients continued all their existing medications except for statins which were discontinued from 1 week prior to the infusion and recommenced following the atherectomy/angioplasty. rHDL and infusion protocol The study was double blinded and the rHDL (CSL Behring AG, Bern, Switzerland; CSL-111; 80 mg/kg; comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150) or placebo (saline) was administered over a 4 hr period as previously described 7 .

Article Title: Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Article Snippet: The rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soy bean in a ratio of 1:150.

Article Title: High-Density Lipoproteins Are Bug Scavengers
Article Snippet: Finally, we recently tested rHDL (CSL-111 from CSL Behring) IV injection two hours after sepsis in three preclinical models: CLP, intraperitoneal injection of E. coli (IAI76 strain) and P. aeruginosa pneumonia.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human ApoA-I or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 is comprised of human apoA-I and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.
Article Snippet: rHDL (CSL-111, CSL Behring) is composed of purified serum derived human apoA-I (hapoA-I) and soy PC, combined at amolar ratio of 1:150 [56].

Article Title: CETP expression reverses the reconstituted HDL-induced increase in VLDL
Article Snippet: Upon randomization according to total plasma cholesterol (TC) and TG levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, Bern, Switzerland) (250 mg/kg in 250 μl PBS) or vehicle.

Article Title: Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity
Article Snippet: Purified human apoAI or rHDL (CSL-111) was provided by CSL Behring AG, Bern, Switzerland; CSL-111 comprises human apoAI and phosphatidylcholine from soybean in a ratio of 1:150.

Article Title: Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Article Snippet: We would like to thank CSL Behring AG, Bern, Switzerland, for supplying the rHDL (CSL-111) and Melissa Formosa and Donna Vizi for assistance with the clinical trial.



Similar Products

90
CSL Behring rhdl csl-111
Rhdl Csl 111, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhdl+csl-111/csl+111/pmc07226336-139-4-7
Average 90 stars, based on 1 article reviews
rhdl csl-111 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
CSL Behring rhdl (csl-111
Rhdl (Csl 111, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhdl+csl-111/csl+111/us09687486-238-1-6
Average 90 stars, based on 1 article reviews
rhdl (csl-111 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
CSL Limited rhdl csl-111 (csl ltd, parkville, australia)
The CD34 + progenitor cells (A and B) and CD34 + /KDR + endothelial progenitor cells (C and D) were quantified in blood samples collected at baseline and at follow-up. The follow-up samples for the <t>CSL-111-treated</t> group were obtained 16 ± 4 days following completion of the 4 weekly rHDL infusions. Each box plot in A and C shows the median, the interquartile range, the maximum and the minimum of the relative change. B and D show absolute numbers of CD34 + (B) and CD34 + /KDR + (D) endothelial progenitor cell count at baseline and at follow-up. p < 0.05 between groups (A and B), p = N.S. (C and D) from Mann-Whitney tests.* one outlier (baseline cell count 1.6/μl, follow-up 0.1/μl) not presented in figure due to axis limits.
Rhdl Csl 111 (Csl Ltd, Parkville, Australia), supplied by CSL Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhdl+csl-111/purified+human+apoa+i+combined+with+soybean+phosphatidylcholine++csl+111+/pmc05218493-44-15-17
Average 90 stars, based on 1 article reviews
rhdl csl-111 (csl ltd, parkville, australia) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
CSL Behring lyophilized rhdl csl-111
The CD34 + progenitor cells (A and B) and CD34 + /KDR + endothelial progenitor cells (C and D) were quantified in blood samples collected at baseline and at follow-up. The follow-up samples for the <t>CSL-111-treated</t> group were obtained 16 ± 4 days following completion of the 4 weekly rHDL infusions. Each box plot in A and C shows the median, the interquartile range, the maximum and the minimum of the relative change. B and D show absolute numbers of CD34 + (B) and CD34 + /KDR + (D) endothelial progenitor cell count at baseline and at follow-up. p < 0.05 between groups (A and B), p = N.S. (C and D) from Mann-Whitney tests.* one outlier (baseline cell count 1.6/μl, follow-up 0.1/μl) not presented in figure due to axis limits.
Lyophilized Rhdl Csl 111, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhdl+csl-111/csl+111/pmc06419536-133-1-5
Average 90 stars, based on 1 article reviews
lyophilized rhdl csl-111 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
CSL Behring reconstituted hdls (rhdls) csl-111
The CD34 + progenitor cells (A and B) and CD34 + /KDR + endothelial progenitor cells (C and D) were quantified in blood samples collected at baseline and at follow-up. The follow-up samples for the <t>CSL-111-treated</t> group were obtained 16 ± 4 days following completion of the 4 weekly rHDL infusions. Each box plot in A and C shows the median, the interquartile range, the maximum and the minimum of the relative change. B and D show absolute numbers of CD34 + (B) and CD34 + /KDR + (D) endothelial progenitor cell count at baseline and at follow-up. p < 0.05 between groups (A and B), p = N.S. (C and D) from Mann-Whitney tests.* one outlier (baseline cell count 1.6/μl, follow-up 0.1/μl) not presented in figure due to axis limits.
Reconstituted Hdls (Rhdls) Csl 111, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhdl+csl-111/csl+111/10__1161_slash_atvbaha__112__00009-510-1-28
Average 90 stars, based on 1 article reviews
reconstituted hdls (rhdls) csl-111 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


The CD34 + progenitor cells (A and B) and CD34 + /KDR + endothelial progenitor cells (C and D) were quantified in blood samples collected at baseline and at follow-up. The follow-up samples for the CSL-111-treated group were obtained 16 ± 4 days following completion of the 4 weekly rHDL infusions. Each box plot in A and C shows the median, the interquartile range, the maximum and the minimum of the relative change. B and D show absolute numbers of CD34 + (B) and CD34 + /KDR + (D) endothelial progenitor cell count at baseline and at follow-up. p < 0.05 between groups (A and B), p = N.S. (C and D) from Mann-Whitney tests.* one outlier (baseline cell count 1.6/μl, follow-up 0.1/μl) not presented in figure due to axis limits.

Journal: PLoS ONE

Article Title: Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34 + Cells in Patients after an Acute Coronary Syndrome

doi: 10.1371/journal.pone.0168448

Figure Lengend Snippet: The CD34 + progenitor cells (A and B) and CD34 + /KDR + endothelial progenitor cells (C and D) were quantified in blood samples collected at baseline and at follow-up. The follow-up samples for the CSL-111-treated group were obtained 16 ± 4 days following completion of the 4 weekly rHDL infusions. Each box plot in A and C shows the median, the interquartile range, the maximum and the minimum of the relative change. B and D show absolute numbers of CD34 + (B) and CD34 + /KDR + (D) endothelial progenitor cell count at baseline and at follow-up. p < 0.05 between groups (A and B), p = N.S. (C and D) from Mann-Whitney tests.* one outlier (baseline cell count 1.6/μl, follow-up 0.1/μl) not presented in figure due to axis limits.

Article Snippet: Briefly, ERASE was a randomized, double-blind, placebo-controlled, multicentre trial which evaluated the effects of the rHDL CSL-111 (CSL Ltd, Parkville, Australia) on plaque burden as assessed by intravascular ultrasonography in patients who were recruited within 2 weeks of an ACS, defined as unstable angina, non-ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI.

Techniques: Cell Counting, MANN-WHITNEY

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors (n = 7) and plated on fibronectin-coated plates in the absence or presence of CSL-111 (1 mg/mL) from day 0 to day 4 (D0-4), 4 to 7 (D4-7) or 0 to 7 (D0-7). After 7 days of culture, adherent cells were harvested and analyzed by flow cytometry. (A) All adherent cells were quantified by flow cytometry using cell counting beads for enumeration. (B) CSL-111 treatment increases the total number of CD34 + cells when added to cell culture media at D0-4 and D0-7; CD34 + cells were quantified by flow cytometry. (C) CSL-111 treatment reduces basal apoptosis in eEPCs when added to cell culture media at D0-4 and D0-7. Apoptosis was measured by flow cytometry using Annexin V labeling. Each box plot shows the median, the interquartile range, the maximum and the minimum of the relative change. * indicates p < 0.05 between groups from Wilcoxon signed-rank tests.

Journal: PLoS ONE

Article Title: Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34 + Cells in Patients after an Acute Coronary Syndrome

doi: 10.1371/journal.pone.0168448

Figure Lengend Snippet: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors (n = 7) and plated on fibronectin-coated plates in the absence or presence of CSL-111 (1 mg/mL) from day 0 to day 4 (D0-4), 4 to 7 (D4-7) or 0 to 7 (D0-7). After 7 days of culture, adherent cells were harvested and analyzed by flow cytometry. (A) All adherent cells were quantified by flow cytometry using cell counting beads for enumeration. (B) CSL-111 treatment increases the total number of CD34 + cells when added to cell culture media at D0-4 and D0-7; CD34 + cells were quantified by flow cytometry. (C) CSL-111 treatment reduces basal apoptosis in eEPCs when added to cell culture media at D0-4 and D0-7. Apoptosis was measured by flow cytometry using Annexin V labeling. Each box plot shows the median, the interquartile range, the maximum and the minimum of the relative change. * indicates p < 0.05 between groups from Wilcoxon signed-rank tests.

Article Snippet: Briefly, ERASE was a randomized, double-blind, placebo-controlled, multicentre trial which evaluated the effects of the rHDL CSL-111 (CSL Ltd, Parkville, Australia) on plaque burden as assessed by intravascular ultrasonography in patients who were recruited within 2 weeks of an ACS, defined as unstable angina, non-ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI.

Techniques: Isolation, Flow Cytometry, Cell Counting, Cell Culture, Labeling

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors (n = 3) and plated on fibronectin-coated plates in the absence or presence of CSL-111 (1 mg/mL) from day 0 to day 4 (D0-4), 4 to 7 (D4-7) or 0 to 7 (D0-7). On day 7 of culture, adherent cells were harvested and assayed in a modified Boyden chamber for their capacity to migrate along an SDF-1 gradient. Significantly increased migration was observed among cells treated with CSL-111 for day 0 to day 4 (**; p = 0.0003) and 0 to 7 (*; p = 0.0135) compared to controls. Figure shows adjusted mean±standard error of the mean (SEM). p-values are reported from mixed model ANOVA.

Journal: PLoS ONE

Article Title: Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34 + Cells in Patients after an Acute Coronary Syndrome

doi: 10.1371/journal.pone.0168448

Figure Lengend Snippet: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors (n = 3) and plated on fibronectin-coated plates in the absence or presence of CSL-111 (1 mg/mL) from day 0 to day 4 (D0-4), 4 to 7 (D4-7) or 0 to 7 (D0-7). On day 7 of culture, adherent cells were harvested and assayed in a modified Boyden chamber for their capacity to migrate along an SDF-1 gradient. Significantly increased migration was observed among cells treated with CSL-111 for day 0 to day 4 (**; p = 0.0003) and 0 to 7 (*; p = 0.0135) compared to controls. Figure shows adjusted mean±standard error of the mean (SEM). p-values are reported from mixed model ANOVA.

Article Snippet: Briefly, ERASE was a randomized, double-blind, placebo-controlled, multicentre trial which evaluated the effects of the rHDL CSL-111 (CSL Ltd, Parkville, Australia) on plaque burden as assessed by intravascular ultrasonography in patients who were recruited within 2 weeks of an ACS, defined as unstable angina, non-ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI.

Techniques: Isolation, Modification, Migration